-
Pazopanib, sold
under the
brand name Votrient, is an anti-cancer
medication marketed worldwide by Novartis. It is a
potent and
selective multi-targeted...
-
necessary elements to the
tumor for
tumor survival. Anti-VEGF
agents such as
pazopanib are
approved for use in
carcinomas and in soft
tissue sarcomas such as...
-
tyrosine kinases stimulated by VEGF: sunitinib, sorafenib, axitinib, and
pazopanib (some of
these therapies target VEGF
receptors rather than the VEGFs)...
- and
doxorubicin combination/gemcitabine and docetaxel/trabectedin;
pazopanib is the
targeted therapy used in
metastatic leiomyosarcoma as
second line...
- interferon),
kinase inhibitors (temsirolimus, sunitinib, sorafenib,
pazopanib) and anti-angiogenic
therapies (bevacizumab). "Clear cell carcinoma"....
- This is a list of
adverse effects of the anti-cancer drug
pazopanib,
sorted by
frequency of occurrence. Very
common (>10% incidence)
adverse effects include:...
-
progressive and
locally advanced differentiated thyroid cancer (DTC).
Pazopanib and
axitinib are used
orally for the
treatment of
advanced renal cell...
- most
common toxicity being diarrhea. Imatinib, sunitinib, sorafenib, and
pazopanib have been
studied in the
treatment of
aggressive fibromatosis (desmoid...
- Some
examples of
stems are: -anib for
angiogenesis inhibitors (e.g.
pazopanib) -anserin for
serotonin receptor antagonists,
especially 5-HT2 antagonists...
- cancer, have
shown promising results,
especially in
combination with
pazopanib,
which also
slows the
process of
blood vessel growth.
Bevacizumab has...
